Syndecan-4 levels in bronchoalveolar lavage fluid and serum in non-small cell lung cancer
DOI:
https://doi.org/10.13181/mji.oa.247264Keywords:
lung cancer, non-small cell lung cancer, syndecan-4Abstract
BACKGROUND Lung cancer has the highest cancer-related mortality rate worldwide. Research has been conducted to improve early detection and markers of predictive value but only focused on the expression of syndecan-4 (SDC4) in serum. Studies in bronchoalveolar lavage (BAL) fluids of non-small cell lung cancer (NSCLC) patients are still limited. This study aimed to evaluate the clinical value of SDC4 in serum and BAL in NSCLC patients.
METHODS Blood serum and BAL fluids were obtained from 44 patients with NSCLC and 41 non-cancer patients as the control. The level of SDC4 was measured. The relationships between SDC4 and clinicopathologic factors were also analyzed.
RESULTS Serum SDC4 levels in NSCLC patients were significantly lower than the control group (p = 0.002). Furthermore, the disease stages and serum SDC4 levels had a negative correlation, which was lower in the advanced stage (IIIb/IV) than in the initial stage (I/II/IIIa) (p = 0.517). The same results were obtained from BAL fluids SDC4 levels, which were significantly lower in the advanced stage (IIIb/IV) than in the early stage (I/II/IIIa) (p = 0.007).
CONCLUSIONS Serum SDC4 levels in NSCLC patients were lower than those of non-cancer patients. They also performed different results in disease stages. SDC4 could be a helpful biomarker in NSCLC.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and molecular classification of lung cancer. Cancer Treat Res. 2016;170:25-46. https://doi.org/10.1007/978-3-319-40389-2_2
Tsoyi K, Osorio JC, Chu SG, Fernandez IE, De Frias SP, Sholl L, et al. Lung adenocarcinoma syndecan-2 potentiates cell invasiveness. Am J Respir Cell Mol Biol. 2019;60(6):659-66. https://doi.org/10.1165/rcmb.2018-0118OC
Carvalho AS, Moraes MC, Hyun Na C, Fierro-Monti I, Henriques A, Zahedi S, et al. Is the proteome of bronchoalveolar lavage extracellular vesicles a marker of advanced lung cancer? Cancers (Basel). 2020;12(11):3450. https://doi.org/10.3390/cancers12113450
Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13-29. https://doi.org/10.1016/j.hoc.2016.08.006
Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-based lung cancer screening: a systematic review. Lung Cancer. 2020;147:154-86. https://doi.org/10.1016/j.lungcan.2020.07.007
Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):463-73. https://doi.org/10.1016/j.mcna.2018.12.006
Toba-Ichihashi Y, Yamaoka T, Ohmori T, Ohba M. Up-regulation of syndecan-4 contributes to TGF-v1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells. Biochem Biophys Rep. 2016;5:1-7. https://doi.org/10.1016/j.bbrep.2015.11.021
Onyeisi JOS, Lopes CC, Götte M. Syndecan-4 as a pathogenesis factor and therapeutic target in cancer. Biomolecules. 2021;11(4):503. https://doi.org/10.3390/biom11040503
Güden M, Karaman ST, Basat O. Evaluation of the relationship between the level of addiction and exhaled carbon monoxide levels with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in smokers. Tob Induc Dis. 2022;20:52. https://doi.org/10.18332/tid/149227
Supriyanto DA, Damayanti T. Correlation of smoking habit and level of nicotine dependence in university students. Respir Sci. 2023;3(2):94-102. https://doi.org/10.36497/respirsci.v3i2.54
Masturoh I, Anggita TN. Rekam Medis dan Informasi Kesehatan (RMIK) Metodologi Penelitian Kesehatan. 1st ed. Jakarta: Tim P2M2; 2018.
Keller-Pinter A, Gyulai-Nagy S, Becsky D, Dux L, Rovo L. Syndecan-4 in tumor cell motility. Cancers (Basel). 2021;13(13):3322. https://doi.org/10.3390/cancers13133322
Choi Y, Yun JH, Yoo J, Lee I, Kim H, Son HN, et al. New structural insight of c-terminal region of syntenin-1, enhancing the molecular dimerization and inhibitory function related on syndecan-4 signaling. Sci Rep. 2016;6:36818. https://doi.org/10.1038/srep36818
El Ghazal R, Yin X, Johns SC, Swanson L, Macal M, Ghosh P, et al. Glycan sulfation modulates dendritic cell biology and tumor growth. Neoplasia. 2016;18(5):294-306. https://doi.org/10.1016/j.neo.2016.04.004
Zhu Z, Ling X, Zhou H, Xie J. Syndecan-4 is the key proteoglycan involved in mediating sepsis-associated lung injury. Heliyon. 2023;9(8):e18600. https://doi.org/10.1016/j.heliyon.2023.e18600
Afratis NA, Nikitovic D, Multhaupt HA, Theocharis AD, Couchman JR, Karamanos NK. Syndecans - key regulators of cell signaling and biological functions. FEBS J. 2017;284(1):27-41. https://doi.org/10.1111/febs.13940
Gopal S. Syndecans in inflammation at a glance. Front Immunol. 2020;11:227. https://doi.org/10.3389/fimmu.2020.00227
Jechorek D, Haeusler-Pliske I, Meyer F, Roessner A. Diagnostic value of syndecan-4 protein expression in colorectal cancer. Pathol Res Pract. 2021;222:153431. https://doi.org/10.1016/j.prp.2021.153431
Barbouri D, Afratis N, Gialeli C, Vynios DH, Theocharis AD, Karamanos NK. Syndecans as modulators and potential pharmacological targets in cancer progression. Front Oncol. 2014;4:4. https://doi.org/10.3389/fonc.2014.00004
Onyeisi JOS, Ferreira BZ, Nader HB, Lopes CC. Heparan sulfate proteoglycans as targets for cancer therapy: a review. Cancer Biol Ther. 2020;21(12):1087-94. https://doi.org/10.1080/15384047.2020.1838034
Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, et al. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest. 2014;124(7):3016-31. https://doi.org/10.1172/JCI74270
Liao WC, Yen HR, Chen CH, Chu YH, Song YC, Tseng TJ, et al. CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. Am J Cancer Res. 2021;11(3):812-26.
Lambert J, Makin K, Akbareian S, Johnson R, Alghamdi AA, Robinson SD, et al. ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis. J Cell Sci. 2020;133(7):jcs235762. https://doi.org/10.1242/jcs.235762
Tanino Y, Wang X, Nikaido T, Misa K, Sato Y, Togawa R, et al. Syndecan-4 inhibits the development of pulmonary fibrosis by attenuating TGF-v signaling. Int J Mol Sci. 2019;20(20):4989. https://doi.org/10.3390/ijms20204989
Published
How to Cite
Issue
Section
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
